Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
BOSTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth...
Month: February 2026
Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
ALACHUA, Fla. and TAMPA, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing...
Soleo Health Moves to New Location in St. Louis Metro Due to Continued Growth
FRISCO, Texas and CHESTERFIELD, Mo., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Soleo Health, an innovative leader and national provider of...
Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results
WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a...
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for...
Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide
Mean weight loss of up to 12.1% with no observed plateau at 26 weeks in Phase 2 trial in China...
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead...
Leadership Changes
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT...
Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator
The Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of...
Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting
Pivotal Phase 3 data from RAPIDe-3 of deucrictibant for the on-demand treatment of HAE attacks to be presented for the...
Aleen Inc. Insights: What Are AI Agents and How They Fit Into Digital Wellness
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Aleen Inc. (CSE: ALEN.U), a digital wellness company, shares an educational overview...
Neural Portfolio Company Hanf.com Reports Strong Fiscal 2025 Results with 58% Revenue Growth and Positive Normalized Operating Income
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an...
Beckett’s Launches in BevMo! Stores Across California
Award-winning non-alcoholic brand expands California retail footprint with top selling Gin & Tonic and Moscow Mule canned cocktailsToronto, Ontario and...
Cardiol Therapeutics’ ARCHER Phase II Study Results Published in ESC Heart Failure
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a...
Rapid Dose Therapeutics Launches QuickStrip(TM) Medical Cannabis for Patients in Brazil following ANVISA Approval of Sublingual and Buccal Formats for Medical Treatment
Burlington, Ontario--(Newsfile Corp. - February 10, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company") ,...
Therma Bright Portfolio Update: Inretio Successfully Completes First-in-Human Cohort for PREVA(TM) Stroke Platform; Targets 2026 U.S. FDA Trial
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the...
Phio Announces Safety Monitoring Committee’s (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial
Maximum Dose Concentration in Final Cohort Yields 85% Pathological Response (6 of 7 Patients); Complete Response (100% Tumor Clearance) in...
Oscar Health Announces Financial Results for Fourth Quarter and Full-Year 2025
Achieves Record Membership of ~3.4 Million and Provides Full-Year 2026 Outlook Including More Than $18 Billion in RevenueNEW YORK--(BUSINESS WIRE)--Oscar...
Calla Lily Clinical Care and Merck Announce Strategic Collaboration to Advance Intravaginal Drug Delivery Platform
Enhancing patient treatment experience and care with a new self-administered solution for vaginal therapeutics Versatile platform technology developed from a...
Protai to showcase groundbreaking AIMS™ drug discovery platform and best-in-class PRT001 KAT6A degrader results at spring 2026 global conferences.
TEL AVIV, Israel, Feb. 10, 2026 /PRNewswire/ -- Protai, www.protai.bio, an AI drug discovery startup, announced its participation in a series of...